Publications

Petit T, Benider A, Yovine A, Bougnoux P, Spaeth D, Maindrault-Goebel F, Serin D, Tigaud JD, Eymard JC, Simon H, Bertaux B, Brienza S, Cvitkovic E.

Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Anticancer Drugs. 2006 Mar; 17(3):337-43.

Mitry E, Ducreux M, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouche O, Etienne PL, Tigaud JM, Morvan F, Cvitkovic E, Rougier P.

Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. Gastroenterol Clin Biol. 2006 Mar;30(3):357-63 .

Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu PH, Delva R, Lotz JP, Belle SV, Extra JM, Cvitkovic E.

 A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann Oncol. 2006 Mar; 17(3):429-36.

Hilgers W, Faivre S, Chieze S, Alexandre J, Lokiec F, Goldwasser F, Raymond E, Kahatt C, Taamma A, Weems G, MacDonald JR, Misset JL, Cvitkovic E.

A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors. Invest New Drugs. 2006 Jul; 24(4):311-9. 12.

Serova M , Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen AK, Laar ES, Waters SJ, Cvitkovic E, Raymond E.

Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer Chemother Pharmacol. 2006 Apr; 57(4):491-9.

Serova M , Ghoul A, Benhadji KA, Cvitkovic E, Faivre S, Calvo F, Lokiec F, Raymond E.

Preclinical and clinical development of novel agents that target the protein kinase C family. Semin Oncol. 2006 Aug; 33(4):466-78. Review.

Ghoul A, Serova M, Benhadji KA, Cvitkovic E, Faivre S, Philips E, Calvo F, Lokiec F, Raymond E.

Protein Kinase C a & d Are Members of a Large Kinase Family of High Potential for Novel Anticancer Targeted Therapy. Targeted oncology. 2005. N1, p. 34-47.

Paci A, Rezai K, Deroussent A, De Valeriola D, Re M, Weill S, Cvitkovic E, Kahatt C, Shah A, Waters S, Weems G, Vassal G, Lokiec F.

Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors. Drug Metab Dispos. 2006 Nov; 34(11):1918-26.

Delozier T, Guastalla JP, Yovine A, Levy C, Chollet P, Mousseau M, Delva R, Coeffic D, Vannetzel JM, Zazzi ES, Brienza S, Cvitkovic E.

A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracyclinepretreated and taxane-pretreated metastatic breast cancer. Anticancer Drugs. 2006 Oct; 17(9):1067-73.

Voland C, Bord A, Peleraux A, Penarier G, Carriere D, Galiegue S, Cvitkovic E, Jbilo O, Casellas P.

Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther. 2006 Sep; 5(9):2149-57.

Ma L, Serova M, Podgorniak MP, Berthois Y, Mourah S, Calvo F.

 Amphiregulin antisense RNA expression inhibits angiogenesis of human breast cancer in nude mice. Zhonghua Zhong Liu Za Zhi. 2005 Sep; 27(9):521-3.

Serova M, Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen AK, Laar ES, Waters SJ, Cvitkovic E, Raymond E.

Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer Chemother Pharmacol. 2005 Aug 2; 57(4):491-9